LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 116 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $32,090 | -32.6% | 32,177 | 0.0% | 0.01% | -44.4% |
| Q1 2024 | $47,622 | +6.7% | 32,177 | -21.4% | 0.01% | 0.0% |
| Q4 2023 | $44,615 | -55.0% | 40,931 | -51.2% | 0.01% | -59.1% |
| Q3 2023 | $99,039 | -16.3% | 83,931 | 0.0% | 0.02% | -18.5% |
| Q2 2023 | $118,343 | +6.7% | 83,931 | +13.5% | 0.03% | -3.6% |
| Q1 2023 | $110,897 | +12.9% | 73,931 | -11.9% | 0.03% | -12.5% |
| Q4 2022 | $98,199 | +3.4% | 83,931 | 0.0% | 0.03% | 0.0% |
| Q3 2022 | $95,000 | -24.0% | 83,931 | +6.3% | 0.03% | -22.0% |
| Q2 2022 | $125,000 | +6.8% | 78,931 | +4.0% | 0.04% | +20.6% |
| Q1 2022 | $117,000 | -10.0% | 75,931 | +43.5% | 0.03% | -10.5% |
| Q4 2021 | $130,000 | +7.4% | 52,931 | +10.4% | 0.04% | -5.0% |
| Q3 2021 | $121,000 | -11.7% | 47,931 | 0.0% | 0.04% | -13.0% |
| Q2 2021 | $137,000 | +29.2% | 47,931 | +6.7% | 0.05% | +9.5% |
| Q1 2021 | $106,000 | – | 44,931 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $52,403,228 | 3.69% |
| Raffles Associates | 1,536,946 | $2,305,419 | 3.14% |
| Defender Capital, LLC. | 5,136,085 | $7,704,128 | 2.69% |
| Prescott General Partners LLC | 1,851,851 | $2,777,777 | 0.22% |
| DAFNA Capital Management LLC | 140,000 | $210,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $67,500 | 0.05% |
| CTC Capital Management, LLC | 14,100 | $21,150 | 0.04% |
| Diametric Capital, LP | 50,875 | $76,313 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $1,172,649 | 0.03% |
| One68 Global Capital, LLC | 13,377 | $20,066 | 0.03% |